Finivi Inc’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.29M Sell
5,240
-181
-3% -$185K 3.22% 8
2026
Q1
$4.99M Buy
5,421
+725
+15% +$735K 2.72% 11
2025
Q4
$5.05M Sell
4,696
-224
-5% -$214K 2.92% 10
2025
Q3
$3.75M Buy
4,920
+95
+2% +$70.7K 2.39% 12
2025
Q2
$3.76M Buy
4,825
+172
+4% +$134K 2.55% 11
2025
Q1
$3.84M Buy
4,653
+42
+0.9% +$34.9K 3.09% 10
2024
Q4
$3.56M Sell
4,611
-37
-0.8% -$30.6K 2.84% 10
2024
Q3
$4.12M Sell
4,648
-401
-8% -$361K 3.34% 8
2024
Q2
$4.57M Buy
5,049
+39
+0.8% +$31.2K 3.79% 5
2024
Q1
$3.9M Buy
5,010
+33
+0.7% +$23.5K 3.53% 5
2023
Q4
$2.9M Buy
+4,977
New +$2.91M 2.83% 7

Other funds holding LLY

Finivi Inc's LLY Position: Q2 2026 in Review

Finivi Inc reduced its Eli Lilly (LLY) stake by 3.3% in Q2 2026, selling an estimated $185K and leaving 5,240 shares worth $6.29M. The position accounts for 3.22% of the portfolio, ranked #8.

Finivi Inc first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 4,543 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Finivi Inc held 5,240 shares of Eli Lilly worth $6.29M as of Q2 2026.
  • Finivi Inc sold 181 Eli Lilly shares in Q2 2026, an estimated $185K.
  • Eli Lilly made up 3.22% of Finivi Inc's portfolio in Q2 2026, its #8 holding.
  • Finivi Inc first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 4,543 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Finivi Inc's 13F filing for Q2 2026, filed 9 Jul 2026.